NCT04321395View on ClinicalTrials.gov

Vigabatrin and Insulin Sensitivity

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

May 15, 2024

Conditions
NAFLDObesity
Interventions
DRUG

Vigabatrin

Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.

Trial Locations (1)

63110

Washington University in St. Louis, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT04321395 - Vigabatrin and Insulin Sensitivity | Biotech Hunter | Biotech Hunter